Current status of biomedical products for gene and cell therapy of recessive dystrophic epidermolysis bullosa (review, part IV)
- 11 November 2025
- journal article
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 24 (5) , 551-557
Abstract
Recessive dystrophic epidermolysis bullosa (RDEB) is one of the main types of epidermolysis bullosa, a rare, severe, genetic disease characterized by systemic chronic inflammation, blisters, erosions and extensive chronic wounds on the skin and a tendency to squamous cell carcinoma development. The disease is caused by pathogenic variant of COL7A1 gene encoding the synthesis of type VII collagen (C7), that is the main component of the anchorage fibrils, which maintain the adhesion between the epidermis and the underlying dermis. The disease is debilitating. Treatment methods mainly include supportive measures so the development of treatment methods that directly affect the cause of the disease is very relevant. The article is devoted to the possibility of using one of the most promising treatment strategies of RDEB — gene editing in patients with RDEB by means of specific nucleases, namely TALEN (Transcription activator-like effector nucleases) and CRISPR/Cas (Clustered Regularly Interspaced Short Palindromic Repeats/Crispr-Associated protein) that allows to almost irreversibly restore the C7 synthesis. The method is at preclinical stage. The results of preclinical studies, comparative analysis of used methods, as well as approaches that may help to implement this method of RDEB gene therapy in clinical practice in the nearest future are presented.Keywords
This publication has 45 references indexed in Scilit:
- Clinical Perspectives of Gene-Targeted Therapies for Epidermolysis BullosaDermatology and Therapy, 2021
- Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosaJournal of the American Academy of Dermatology, 2020
- Efficient Gene Reframing Therapy for Recessive Dystrophic Epidermolysis Bullosa with CRISPR/Cas9Journal of Investigative Dermatology, 2019
- Gene Therapy for Epidermolysis BullosaJournal of Investigative Dermatology, 2019
- Epidermolysis bullosa: Molecular pathology of connective tissue components in the cutaneous basement membrane zoneMatrix Biology, 2018
- Deletion of a Pathogenic Mutation-Containing Exon of COL7A1 Allows Clonal Gene Editing Correction of RDEB Patient Epidermal Stem CellsMolecular Therapy Nucleic Acids, 2018
- 591 A phase 1/2 study of genetically-corrected, collagen VII expressing autologous human dermal fibroblasts injected into the skin of patients with recessive dystrophic epidermolysis bullosa (RDEB)Journal of Investigative Dermatology, 2018
- Traceless Targeting and Isolation of Gene-Edited Immortalized Keratinocytes from Epidermolysis Bullosa Simplex PatientsMolecular Therapy - Methods & Clinical Development, 2017
- Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis BullosaJAMA, 2016
- A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosaJournal of the American Academy of Dermatology, 2013